BioNumerik Pharmaceuticals, Inc. (BioNumerik)

Oncology Corporate Profile

HQ Location

8122 Datapoint Drive, Suite 1250
San Antonio, TX 78229

Company Description

BioNumerik's vision is to discover and develop innovative new cancer treatments by the integration of medicine, pharmaceutical sciences, physics-based molecular simulation and high-performance information technology.

Website: http://www.bionumerik.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Karenitecin_ / karenitecin / BNP1350highly lipophilic camptothecinOvarian cancerIII
Tavocept_ / dimesna / BNP7787chemoprotective agent1st line metastatic Breast cancerIII
Tavocept_ / dimesna / BNP7787chemoprotective agentNon Small Cell Lung Cancer (NSCLC)III
Karenitecin_ / karenitecin / BNP1350highly lipophilic camptothecinAdult malignant GliomaII
Karenitecin_ / karenitecin / BNP1350highly lipophilic camptothecinMelanomaII
Karenitecin_ / karenitecin / BNP1350highly lipophilic camptothecinNon Small Cell Lung Cancer (NSCLC)II
Karenitecin_ / karenitecin / BNP1350highly lipophilic camptothecinOvarian cancerII
MDAMnon-polyglutamylatable antifolateVarious cancer typesI
Karenitecin_ / karenitecin / BNP1350highly lipophilic camptothecin2nd line metastatic GliomaI
Karenitecin_ / karenitecin / BNP1350highly lipophilic camptothecinVarious cancer typesI
Tavocept_ / dimesna / BNP7787chemoprotective agentVarious cancer typesI

View additional information on product candidates here »

Source


http://www.bionumerik.com/

Recent News Headlines

There are no news items to display